Spruce Biosciences (SPRB) Return on Capital Employed (2020 - 2026)
Spruce Biosciences (SPRB) posted quarterly Return on Capital Employed of 79.44% for Q1 2026, up 17540.0% year-over-year from N/an in Q1 2025, and up 47.61% quarter-over-quarter from 151.63% in Q4 2025.
Spruce Biosciences (SPRB) Return on Capital Employed (2020 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Return on Capital Employed for 7 consecutive years, with 79.44% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 17540.0% year-over-year to 79.44%; the TTM figure through Mar 2026 stood at 79.44% (up 17540.0% YoY), while the FY2025 annual figure was 93.55%, up 109.0% from the prior year.
- Return on Capital Employed grew to 79.44% in Q1 2026 per SPRB's latest filing, from 151.63% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 39.35% in Q1 2022 and bottomed at 541.46% in Q3 2025.
- Historically, Return on Capital Employed has averaged 121.38% across 5 years, with a median of 66.49% in 2024.
- Annual changes were most pronounced in 2025 — Return on Capital Employed tumbled 46749 bps — and 2026, when it surged 17540 bps.
- Spruce Biosciences' Return on Capital Employed stood at 60.6% in 2022, then retreated by 2 bps to 61.9% in 2023, then tumbled by 127 bps to 140.7% in 2024, then slipped by 8 bps to 151.63% in 2025, then soared by 48 bps to 79.44% in 2026.
- Business Quant data shows SPRB's Return on Capital Employed at 79.44% in Q1 2026, 151.63% in Q4 2025, and 541.46% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.96 Bn | 132.11 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.20 Bn | 55.06 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.19 Bn | 37.09 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.43 Bn | 28.12 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 7.88% |
| 10 | Spruce Biosciences | 124.96 Mn | 124.96 Mn | - | -69.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -69.78% |
| Mar 31, 2026 | -79.44% |
| Dec 31, 2025 | -151.63% |
| Sep 30, 2025 | -541.46% |
| Jun 30, 2025 | -271.31% |
| Mar 31, 2025 | -254.84% |
| Dec 31, 2024 | -140.70% |
| Sep 30, 2024 | -73.98% |
| Jun 30, 2024 | -70.62% |
| Mar 31, 2024 | -66.49% |
| Dec 31, 2023 | -61.90% |
| Sep 30, 2023 | -55.56% |
| Jun 30, 2023 | -46.30% |
| Mar 31, 2023 | -54.54% |
| Dec 31, 2022 | -60.60% |
| Sep 30, 2022 | -50.40% |
| Jun 30, 2022 | -44.31% |
| Mar 31, 2022 | -39.35% |
| Dec 31, 2021 | -34.50% |
| Sep 30, 2021 | -31.69% |